Crohn's Disease Clinical Research Trials

Birmingham : Achieve Clinical Research, LLC an Accel Research Site

A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and efficacy of AMG 181 in subjects with Moderate to Severe Crohn's Disease

Birmingham : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Mobile :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Goodyear : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Little Rock : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Phoenix :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Scottsdale : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Scottsdale : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Tucson : Novo Nordisk Clinical Trial Call Center

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Tucson : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Tucson :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Tucson :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Tucson : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Tucson : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Tucson : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Little Rock : Novo Nordisk Clinical Trial Call Center

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Little Rock : Preferred Research Partners Inc

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Little Rock : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Little Rock : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Corona : TRIMED Clinical Trials

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Glendale : Research Site

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

La Jolla :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

La Jolla :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

La Jolla : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

La Jolla : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

La Jolla : University of California, San Diego

OTIS Autoimmune Diseases in Pregnancy Project

La Jolla : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Laguna Hills : Novo Nordisk Clinical Trial Call Center

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Los Angeles :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Los Angeles : Cedars Sinai Medical Center Updated

A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

Los Angeles :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Los Angeles :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Oakland :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Orange : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Orange : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

San Carlos : Digestive Care Associates, LLC

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

San Carlos :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

San Diego :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

San Diego :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

San Diego :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

San Diego : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

San Diego : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

San Diego : University of California, San Diego

OTIS Autoimmune Diseases in Pregnancy Project

San Francisco :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

San Francisco : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

San Francisco : University of California, San Francisco

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

San Francisco : University of California, San Francisco

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

San Francisco : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

San Francisco : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Denver : Rocky Mountain Clinical Research

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study of Daikenchuto (TU-100) in Subjects with Moderate Crohn’s Disease

Aurora : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Denver :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Denver : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Denver : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Lafayette : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Lakewood : Rocky Mountain Gastroenterology Associates

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Lakewood : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Lakewood : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Lakewood : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Littleton : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Littleton : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Littleton : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Lone Tree :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Lone Tree :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Thornton : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Thornton : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Hamden : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Hamden : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hamden : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Hartford :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

New Haven :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

New Haven :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Washington : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Washington : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Clearwater : Novo Nordisk Clinical Trial Call Center

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Clearwater : Clinical Research of West Florida, Inc

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Clearwater : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Clearwater : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Clearwater : Clinical Research of West Florida

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Clearwater : Clinical Research of West Florida

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Crystal River : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Crystal River : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Gainesville :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Gainesville : University of Florida Updated

A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

Gainesville :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Gainesville :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Inverness : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Inverness : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Jacksonville :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Jacksonville :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Jacksonville : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Largo : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Largo : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Miami :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Miami : Novo Nordisk Clinical Trial Call Center

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Miami : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Miami : Jackson Memorial Hospital

Prevalence of Cytomegalovirus, Epstein Barr Virus and Human Herpes 6 Virus in Inflammatory Bowel Disease

Miami : Research Site

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

Miami : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Naples : Gastroenterology Group of Naples

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Naples :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Naples :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

New Port Richey : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Orlando :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Orlando : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Orlando : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Port Orange : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Sanford : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Sanford : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Trinity : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Weston :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Winter Park : Shafran Gastroenterology Center

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Winter Park :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Winter Park :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Winter Park : Shafran Gastroenterology Center

Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy

Winter Park : Shafran Gastroenterology Center

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Winter Park : Shafran Gastroenterology Center

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Winter Park : Shafran Gasteroenterology Center

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Atlanta :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Atlanta : Atlanta Gastroenterology Associates, LLC

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Atlanta :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Atlanta :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Atlanta : Atlanta Gastroenterology Associates

Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients

Atlanta : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Atlanta : Atlanta Gastroenterology Associates

Optimizing Cimzia in Crohn's Patients

Atlanta : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Atlanta : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Decatur : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Decatur :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Decatur :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Decatur : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Macon : Gastroenterology Associates of Central Georgia, LLC Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Macon : Gastroenterology Associates of Central Georgia

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Macon :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Macon :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Macon : Gastroenterology Associates of Central Georgia, LLC Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Marietta : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Marietta : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Boise :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Arlington Heights : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Arlington Heights : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Chicago :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Chicago : University of Chicago Hospital Medical Center

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Chicago : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Chicago :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Chicago : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Chicago : University of Chicago Medical Center

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Chicago : University of Chicago

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Chicago : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Chicago : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Evanston : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Evanston :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Glenview : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Oak Lawn : Southwest Gastroenterology Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Indianapolis : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Indianapolis : IU School of Medicine - Gastroenterology

PillCam® Platform With the PillCam Crohn's Disease Capsule

Clive :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Clive :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Clive : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Pratt :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Pratt :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Topeka : Cotton-O'Neil Clinical Research Center

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Topeka : Cotton-O'Neil Clinical Research Center

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Lexington : University of Kentucky Chandler Medical Center

Crohn’s Disease Research Study

Crestview Hills :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Crestview Hills :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Lexington : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Lexington :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Lexington :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Lexington : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Lexington : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Louisville : University of Louisville School of Medicine

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Louisville : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Baton Rouge :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Baton Rouge :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Hammond : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hammond : Gastroenterology Research Of New Orleans

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Hammond : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Monroe : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Monroe : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

New Orleans :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

New Orleans :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

New Orleans :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Portland :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Chevy Chase : MGG Group Co., Inc., Chevy Chase Clinical Research

Ulcerative Colitis and Crohn’s Disease (IBD) Research Study

Annapolis : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Annapolis : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Baltimore :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Baltimore : University of Maryland, Baltimore

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Baltimore : University of Maryland, Baltimore

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Chevy Chase : Metropolitan Gastroenterology Group. PC

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Chevy Chase :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Chevy Chase :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Chevy Chase : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Chevy Chase : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Chevy Chase : Chevy Chase Clinical Research

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Chevy Chase : Chevy Chase Clinical Research

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Chevy Chase : Metropolitan Gastroenterology Group, Pc, Chevy Chase Cr

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Chevy Chase : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Chevy Chase : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Towson : Endoscopic Microsurgery Associates PA

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Towson :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Towson :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Towson : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Boston :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Boston :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Boston :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Boston : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Boston : Boston Medical Center

Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients

Boston : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Boston : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Boston : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Brockton : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Newton : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Quincy : MedRACS

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Worcester :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Worcester :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Worcester :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Worcester : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Worcester : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Ann Arbor : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Ann Arbor :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Ann Arbor :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Ann Arbor : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Ann Arbor : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Chesterfield : Clinical Research Institute of Michigan

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Chesterfield :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Chesterfield :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Chesterfield : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Chesterfield : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Chesterfield : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Chesterfield : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Detroit :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Grand Rapids : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Novi :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Novi :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Troy : Center for Digestive Health Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Troy : Center for Digestive Health

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Troy :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Troy :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Troy : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Troy : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Troy : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Troy : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Wyoming : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Ypsilanti : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Ypsilanti :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Ypsilanti :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Ypsilanti : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Minneapolis :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Rochester :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Rochester :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Rochester : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Rochester : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Rochester : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Saint Paul :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

St. Paul : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

St. Paul : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Ocean Springs : Digestive Health Center

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Ocean Springs :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Ocean Springs :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

St. Louis : Washington University in St. Louis - Center for Clinical Studies

Washington University seeks healthy volunteers and patients with Crohn’s disease for a research study.

Columbia : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Columbia : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Jefferson City : Novo Nordisk Clinical Trial Call Center

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Kansas City : The Children's Mercy Hospital

Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's Disease

Lee's Summit :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Lee's Summit :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Lee's Summit : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Mexico :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Mexico : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Mexico : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Mexico : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Mexico : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

St. Louis : St. Louis Center for Clinical Research

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

St. Louis : St Louis Center for Clinical Studies

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

St. Louis : Saint Louis Center for Clinical Research

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

St. Louis : St. Louis Center for Clinical Studies

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

St. Louis : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Boys Town :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Las Vegas :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Las Vegas :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Lebanon :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Manchester :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Berlin : Research Site

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Egg Harbor Township :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Marlton :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Marlton :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Mays Landing :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Mays Landing : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Mays Landing : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Morristown :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Morristown : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Morristown : Research Site

Safety Study of Entocort for Children With Crohn's Disease

New York : Manhattan Medical Research

A New Approach to Crohn's Disease Treatment

Albany : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Albany : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Brooklyn :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Brooklyn : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Buffalo :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Buffalo : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Buffalo : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Great Neck : Long Island Clinical Research Associates, LLP

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Great Neck :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Great Neck :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Great Neck : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Great Neck : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Great Neck : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Great Neck : Nyu Langone Long Island Clinical Research Associates

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Great Neck : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Great Neck : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Hollis : NY Scientific CORP

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Lake Success : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Lake Success : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Mineola :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

New Hyde Park :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

New York :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

New York : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

New York :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

New York :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

New York : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

New York : Hospital

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

New York : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

New York : Weill Cornell Medical College

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

New York : Mount Sinai School of Medicine

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

New York : Mount Sinai School of Medicine

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

New York : Weill Cornell Medical College

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

New York : Mount Sinai School Of Medicine

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Poughkeepsie : Premier Medical Group of the Hudson Valley, PC Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Poughkeepsie : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Poughkeepsie : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Rochester : Rochester General Hospital Updated

A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

Rochester :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Stony Brook :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Stony Brook : Research Site

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Syracuse :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Charlotte : Piedmont Medical Research

Crohn's Disease Study

Charlotte : PMG Research of Charlotte

Crohn's Disease Study

Raleigh : Wake Research Associates

Treating your Crohn's disease doesn't have to be a solo act.

Salisbury : PMG Research of Salisbury

Is Crohn’s Disease part of your daily life?

Winston-Salem : PMG Research of Winston-Salem

Is Crohn’s Disease part of your daily life?

Chapel Hill :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Chapel Hill :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Chapel Hill :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Chapel Hill : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Chapel Hill : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Chapel Hill : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Chapel Hill : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Charlotte :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Charlotte :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Charlotte : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Charlotte : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Charlotte : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Durham :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Durham : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Greenville : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Raleigh :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Raleigh :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Raleigh : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Raleigh : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Salisbury : PMG Research of Salisbury

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Winston-Salem : PMG Research of Winston-Salem, LLC

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Beavercreek : Dayton Gastroenterology

Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients

Cincinnati : Consultants for Clinical Research

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Cincinnati : Ohio Gastroenterology and Liver

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Cincinnati :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Cincinnati :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Cincinnati : Consultants For Clinical Research

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Cleveland :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Columbus : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Columbus : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Columbus : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Mentor : Great Lakes Gastroenterology Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Mentor : The Endoscopy Center of Lake County Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Mentor : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Mentor : Great Lakes Gastroenterology Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Norman :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Oklahoma City :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Oklahoma City : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Oklahoma City :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Oklahoma City :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Oklahoma City : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Oklahoma City : Research Site

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Tulsa : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Tulsa : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Tulsa : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Tulsa : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Eugene : Clinical Trials of America, Inc

Are you a man or woman over 18, with moderate to severe, active Crohn’s Disease?

Bend :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Bend :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Portland : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Portland : Oregon Health & Science University

Infliximab, Regulatory T Cells, IL2 and Crohn's Disease

Portland : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Danville :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Hershey :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Hershey : Penn State Milton S. Hershey Medical Center

Cimzia Versus Mesalamine for Crohn's Recurrence

King of Prussia : Omnicare Clinical Research, Inc.

Phase II Study of HMPL-004 in Subjects With Crohn's Disease

Philadelphia :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Philadelphia :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Philadelphia :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Philadelphia : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Pittsburgh : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Pittsburgh :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Pittsburgh : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Pittsburgh : Children's Hospital of Pittsburgh of UPMC

Autologous Stem Cell Transplantation for Crohn's Disease

Pittsburgh : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Pittsburgh : University of Pittsburgh

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Greenville :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

North Charleston :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

North Charleston :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Jackson : Novo Nordisk Clinical Trial Call Center

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Knoxville :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Memphis :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Nashville : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Nashville :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Nashville :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Nashville : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Nashville : Inflammatory Bowel Disease Clinic c/o Divison of Gastroenterology, Hepatology and Nutrition, Department of Medicine, School of Medicine, Vanderbilt University

Decisional Influences and Inflammatory Bowel Disease (IBD) Patients' Medication Use

Nashville : Vanderbilt University Medical Center

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Nashville : Vanderbilt University Medical Center

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Nashville : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Nashville : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Nashville : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Austin : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Austin :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Austin :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Austin : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Dallas :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Dallas : Dallas VA Medical Center

Exacerbating Factors in Inflammatory Bowel Disease

Fort Worth :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Grapevine :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Grapevine :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Houston : Novo Nordisk Clinical Trial Call Center

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Houston : Baylor College of Medicine Updated

A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

Houston : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Houston :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Houston :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Houston : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Pasadena : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

San Antonio : Gastroenterology Research Of San Antonio

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Southlake : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Sugar Land : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Tyler : Endoscopy Center of Tyler Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Tyler : Digestive Health Specialists of Tyler Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Tyler :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Tyler :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Tyler : Endoscopy Center of Tyler Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Tyler : Digestive Health Specialists of Tyler Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Ogden : Advanced Research Institute

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Ogden : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Ogden : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Ogden : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Salt Lake City : University of Utah

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Salt Lake City : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Salt Lake City :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Salt Lake City :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Salt Lake City : University of Utah HSC Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Salt Lake City : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Burlington :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Charlottesville :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Charlottesville :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Chesapeake :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Chesapeake :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Christiansburg : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Christiansburg : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Christiansburg : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Danville : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Danville : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Danville : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Fairfax :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Norfolk :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Norfolk : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Norfolk : Gastrointestinal and Liver Specialists Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Richmond : McGuire VA Medical Center Updated

A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

Richmond : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Richmond : McGuire Research Institute

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Richmond : McGuire Research Institute

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Richmond : Research Site

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Virginia Beach :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Virginia Beach :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Seattle :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Seattle : University of Washington Medical Center

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Seattle :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Seattle :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Seattle : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Seattle : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Seattle : University of Washington Medical Center

Induction of Clinical Response Using Rifaximin in Crohn's Disease

Seattle : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Seattle : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Morgantown : United BioSource Corporation

CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring

Madison :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Madison :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Madison :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Madison : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Madison : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Milwaukee :

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

Milwaukee : Wisconsin Center for Advanced Research - GI Associates, LLC Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Milwaukee : The Center for Digestive Health Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Milwaukee : Wisconsin Center for Advanced Research - GI Associates, LLC Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Milwaukee : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Milwaukee : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Milwaukee : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Milwaukee : Wisconsin Center for Advanced Research - GI Associates, LLC Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Wauwatosa : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Wauwatosa : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Adelaide :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Adelaide : Royal Adelaide Hospital

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Adelaide : Royal Adelaide Hospital

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Adelaide : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Adelaide : Research Site

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Adelaide : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Adelaide : Research Site

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

Bankstown : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Bankstown : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Bedford Park :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Box Hill :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Brisbane : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Brisbane : QPharm

Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn’s Disease

Cairns :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Central Queensland M C :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Central Queensland M C :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Concord :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Concord :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Fitzroy : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Fitzroy : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Fremantle :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Fremantle : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Fremantle : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Fremantle : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Garran :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Garran :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Hersten : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hersten : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Herston : Research Site

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Herston : Research Site

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

Kingswood : Nepean Hospital Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Kingswood : Nepean Hospital Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Liverpool :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Liverpool :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Malvern :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Malvern :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Melbourne : Royal Melbourne Hospital

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Melbourne : Royal Melbourne Hospital

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Melbourne : Center for Clinical Studies

Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn’s Disease

Parkville :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Parkville :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Parkville : Monash Medical Centre Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Prahran : Research Site

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Prahran : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Prahran : Research Site

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

South Brisbane : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

South Brisbane : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Innsbruck :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Oberpullendorf : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Oberpullendorf : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Oberpullendorf : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

St. Poelten : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

St. Veit/Glan : Krankenhaus

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

St.Veit/Glan : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Vienna : Site Reference ID/Investigator# 38145

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Wien :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Wien : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Wien : Medizinische Universität

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Wien : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Wien : Pfizer Investigational Site Updated

Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs

Wien : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Wien : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Wien : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Antwerp : UZ Antwerpen

Switching From Adalimumab to Infliximab

Belgium : Belgium

A Study of TRK-170 for the Treatment of Crohn's Disease

Bonheiden : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Bonheiden : Site Reference ID/Investigator# 38147

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Bonheiden : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Bonheiden : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Brussel :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Brussel :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Brussel : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Brussels : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Brussels : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Brussels : Site Reference ID/Investigator# 38149

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Brussels : Pfizer Investigational Site Updated

Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs

Brussels : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Brussels : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Bruxelles : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Edegem : Site Reference ID/Investigator# 43966

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Genk : Hospital Oost-Limburg

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Gent : Gent University Hospital

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Gent : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Gent : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Gent : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Ghent : University Hospital Ghent

Switching From Adalimumab to Infliximab

Hasselt : Virga Jesse hospital

Switching From Adalimumab to Infliximab

Kortrijk : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Kortrijk : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Kortrijk : AZ Groeninge

Switching From Adalimumab to Infliximab

Leuven :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Leuven :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Leuven : Leuven University Hospital

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Leuven : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Leuven : Site Reference ID/Investigator# 38151

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Leuven : Pfizer Investigational Site Updated

Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs

Leuven : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Leuven : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Leuven : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Leuven : UZ Leuven

Switching From Adalimumab to Infliximab

Liege :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Liege : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Liege : Site Reference ID/Investigator# 38150

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Liege : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Mouscron : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Mouscron : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Oostende : AZ Damiaan

Switching From Adalimumab to Infliximab

Ottignies : Clinique Saint-Pierre

Switching From Adalimumab to Infliximab

Roeselare : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Roeselare : Hospital Hartziekenhuis

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Roeselare : Site Reference ID/Investigator# 38146

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Roeselare : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Roeselare : Heilig Hartziekenhuis Roeselare

Switching From Adalimumab to Infliximab

Curitiba : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Curitiba : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Goiania : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Goiás :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Ilha do Fundao - Rio de Janeiro : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Porto Alegre : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Porto Alegre :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Porto Alegre :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Rio de Janeiro : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Rio De Janeiro :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Rio De Janeiro :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Sao Paulo : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Sao Paulo :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

São Paulo :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Bulgaria : Bulgaria

A Study of TRK-170 for the Treatment of Crohn's Disease

Pleven :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Pleven :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Rousse :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Rousse :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Sofia :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Sofia :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Sofia : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Varna :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Varna :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Brandon :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Brandon :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Calgary : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Calgary :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Calgary :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Calgary : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Calgary : Site Reference ID/Investigator# 38156

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Calgary : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Calgary : Division of Gastroenterology

Metabolomic Analysis, a Potential Tool to Direct Treatment With Adalimumab in Crohn's Disease (CD)

Calgary : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Edmonton :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Edmonton :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Edmonton : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Edmonton : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Halifax : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Halifax : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Halifax : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Halifax : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Hamilton :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Hamilton : Site Reference ID/Investigator# 45062

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Hamilton : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Kingston :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Kingston :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

London : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

London :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

London :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

London : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

London : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

London : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

London : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

London : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Montreal : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Montreal :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Montreal :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Montreal : Hopital Maisonneuve-Rosemont Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Montreal : Innovaderm Research Inc.

Adalimumab-psoriasis and Small Bowel Lesions

Montreal : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Montreal : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Montreal : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Oshawa : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Ottawa : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Quebec : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Quebec : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Quebec City : Site Reference ID/Investigator# 38157

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Toronto : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Toronto :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Toronto : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Toronto : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Vancouver :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Vancouver :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Vancouver : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Vancouver : Site Reference ID/Investigator# 45502

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Vancouver : Research Site

Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.

Vancouver : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Vancouver : Gastrointestinal Research Institute

Safety and Treatment Effect of QBECO in Moderate to Severe Crohn's Disease

Vancouver : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Vaughan : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Vaughan : Site Reference ID/Investigator# 38155

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Vaughan : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Victoria : PerCuro Clinical Research Limited Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Victoria : Office of Dr. David C. Pearson Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Victoria : Office of Drs Ranjit A. Singh, Jamie D. Papp Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Victoria : Office of Drs. Ranjith Andrew Singh and Jamie D. Papp Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Victoria : PerCuro Clinical Research Limited Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Victoria : Office of Dr. David C. Pearson Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Winnipeg :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Winnipeg : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Winnipeg : Site Reference ID/Investigator# 38152

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Winnipeg : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Avenija Gojka Suska 6 :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Osijek :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Rijeka :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Rijeka :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Zagreb :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Czech Republic : Czech Republic

A Study of TRK-170 for the Treatment of Crohn's Disease

Hradec Kralove :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Hradec Kralove : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Hradec Králové : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hradec Králové : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Hradec Kralove 12 : Site Reference ID/Investigator# 38159

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Olomouc :

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Olomouc : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Olomouc : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Ostrava - Vitkovice : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Prague 7 : Site Reference ID/Investigator# 38158

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Praha 10 : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Praha 4 : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Praha 4 : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Praha 4 : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Praha 7 : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Praha 7 : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Praha 7 : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Praha 9 : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Usti nad Labem : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Usti Nad Labem :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Usti nad Labem : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Aalborg : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Aalborg : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Aalborg : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Aalborg : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Aarhus : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Aarhus : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Aarhus : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Aarhus C : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Herlev : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Herlev :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Herlev : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Herlev : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Herlev : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Herlev : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Herlev : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Hilleroed : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Hilleroed : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Hvidovre : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Hvidovre : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Hvidovre : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Hvidovre : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hvidovre : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

KÃ¸ge : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Koebenhavn : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Koebenhavn : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Koebenhavn NV : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Koebenhavn NV : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Koege : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Koege : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Odense : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Odense : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Odense C : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Silkeborg :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Tallinn : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Tallinn : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Tartu : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Tartu : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Tartu : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Amiens :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Amiens : Site Reference ID/Investigator# 38164

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Amiens CEDEX 01 : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Amiens Cedex 1 :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Amiens Cedex 1 : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Bordeaux :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Bordeaux cedex : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Caen Cedex 9 :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Clichy : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Clichy cedex : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Clichy cedex : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Clichy Cedex : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

France : France

A Study of TRK-170 for the Treatment of Crohn's Disease

Lille :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Lille Cedex : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Lille Cedex : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Lille Cedex : Site Reference ID/Investigator# 38163

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Lille cedex : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Marseille :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Marseilles Cedex 20 : Site Reference ID/Investigator# 64742

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Nice : Site Reference ID/Investigator# 42839

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Nice : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

NICE Cedex 3 : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Paris :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Paris :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Paris : Hôpital Necker Enfants Malades, Faculté de Médecine Necker, INSERM EMI0212

Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis

Paris Cedex 10 : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Paris Cedex 10 : Site Reference ID/Investigator# 38165

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Paris cedex 10 : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Paris cedex 10 : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Paris Cedex 12 : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Paris Cedex 12 : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Pessac :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Pessac : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Pessac Cedex : Site Reference ID/Investigator# 42818

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Reims :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Rouen :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Rouen : Site Reference ID/Investigator# 43222

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Rouen : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Saint-Priest en Jarez : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Saint-Priest en Jarez : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

St Priest En Jarez : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Toulouse :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Vandoeuvre Les Nancy : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Vandoeuvre Les Nancy :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Vandoeuvre Les Nancy :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Vandoeuvre Les Nancy : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Vandoeuvre Les Nancy : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Vandoeuvre les Nancy Cedex : Site Reference ID/Investigator# 66182

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Aachen : Site Reference ID/Investigator# 58770

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Aichhalden : Site Reference ID/Investigator# 91100

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Altenburg : Site Reference ID/Investigator# 48900

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Altenholz : Site Reference ID/Investigator# 64006

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Alzey : Site Reference ID/Investigator# 35047

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Augsburg : Site Reference ID/Investigator# 35062

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bad Berka : Site Reference ID/Investigator# 48899

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bad Homburg : Site Reference ID/Investigator# 58751

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bad Homburg : Site Reference ID/Investigator# 67702

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bad Lausick : Site Reference ID/Investigator# 48888

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bad Salzungen : Site Reference ID/Investigator# 53216

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bad Wildungen : Site Reference ID/Investigator# 73842

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Baden-Baden : Site Reference ID/Investigator# 73847

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Baden-Baden : Site Reference ID/Investigator# 91099

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bayreuth : Site Reference ID/Investigator# 53217

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bayreuth : Site Reference ID/Investigator# 33443

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Berlin :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Berlin :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Berlin : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Berlin : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Berlin : Site Reference ID/Investigator# 34240

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 33698

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 58758

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 33684

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 33701

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 48883

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 33699

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 34248

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 33645

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 33700

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 33663

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 33706

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 34242

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 91101

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 58749

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 33455

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 6070

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 34244

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 33679

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 73846

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 58764

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Site Reference ID/Investigator# 33671

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Berlin : Pfizer Investigational Site Updated

Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs

Berlin : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Berlin : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Berlin : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Bernau : Site Reference ID/Investigator# 73834

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Biberach : Site Reference ID/Investigator# 105656

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bielefeld : Site Reference ID/Investigator# 34278

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bitburg : Site Reference ID/Investigator# 73835

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bitterfeld : Site Reference ID/Investigator# 34281

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bochum :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Bochum : Site Reference ID/Investigator# 58765

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bonn : Site Reference ID/Investigator# 73843

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bonn : Site Reference ID/Investigator# 53273

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bonn : Site Reference ID/Investigator# 53237

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bonn : Site Reference ID/Investigator# 53253

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Brandenburg : Site Reference ID/Investigator# 34304

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Braunschweig : Klinikum Braunscheweig

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Braunschweig : Site Reference ID/Investigator# 35654

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bremen : Site Reference ID/Investigator# 48902

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bremerhaven : Site Reference ID/Investigator# 105638

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Bremervoerde : Site Reference ID/Investigator# 34690

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Buchholz : Site Reference ID/Investigator# 48884

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Buende : Site Reference ID/Investigator# 34693

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Buende : Site Reference ID/Investigator# 53178

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Burglengenfeld : Site Reference ID/Investigator# 53282

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Chemnitz : Site Reference ID/Investigator# 34702

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Chemnitz : Site Reference ID/Investigator# 34701

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Chemnitz : Site Reference ID/Investigator# 53143

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Coburg : Site Reference ID/Investigator# 34705

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Coesfeld : Site Reference ID/Investigator# 34706

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Coesfeld : Site Reference ID/Investigator# 53152

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Cologne : Site Reference ID/Investigator# 53124

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Cottbus : Site Reference ID/Investigator# 34713

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Cottbus : Site Reference ID/Investigator# 53342

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Cottbus : Site Reference ID/Investigator# 34714

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Dachau : Site Reference ID/Investigator# 53285

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Darmstadt : Site Reference ID/Investigator# 35624

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Darmstadt : Site Reference ID/Investigator# 34719

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Darmstadt : Site Reference ID/Investigator# 35623

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Darmstadt : Site Reference ID/Investigator# 53157

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Datteln : Site Reference ID/Investigator# 34721

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Detmold : Site Reference ID/Investigator# 58776

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Dingolfing : Site Reference ID/Investigator# 34732

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Dinkelsbuehl : Site Reference ID/Investigator# 34733

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Dippoldiswalde : Site Reference ID/Investigator# 34735

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Dortmund : Site Reference ID/Investigator# 34743

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Dresden : Site Reference ID/Investigator# 34757

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Dresden : Site Reference ID/Investigator# 35638

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Dresden : Site Reference ID/Investigator# 73841

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Dresden : Site Reference ID/Investigator# 34745

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Dresden : Site Reference ID/Investigator# 34761

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Duesseldorf : Site Reference ID/Investigator# 34770

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Ebern : Site Reference ID/Investigator# 48895

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Eichstaett : Site Reference ID/Investigator# 99800

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Eisenach : Site Reference ID/Investigator# 48898

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Ellefeld : Site Reference ID/Investigator# 34791

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Emden : Site Reference ID/Investigator# 34798

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Erfurt : Site Reference ID/Investigator# 34806

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Erlangen :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Erlangen : Site Reference ID/Investigator# 35192

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Erlangen : Site Reference ID/Investigator# 34818

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Erlangen : Site Reference ID/Investigator# 34819

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Erlangen : Department of Medicine I, University of Erlangen-Nuremberg

Endomicroscopy in IBD Patients

Eschweiler : Site Reference ID/Investigator# 34822

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Essen : Site Reference ID/Investigator# 34826

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Essen : Site Reference ID/Investigator# 91102

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Essen : Site Reference ID/Investigator# 53168

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Euskirchen : Site Reference ID/Investigator# 53165

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Frankfurt : Site Reference ID/Investigator# 34835

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Frankfurt : Site Reference ID/Investigator# 34850

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Frankfurt : Site Reference ID/Investigator# 34836

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Frankfurt Am Main :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Frankfurt Am Main :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Frankfurt am Main : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Frankfurt am Main : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Frankfurt/Main : Klinikum Frankfurt

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Freiburg :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Freiburg : Site Reference ID/Investigator# 34862

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Freiburg : Site Reference ID/Investigator# 34858

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Freital : Site Reference ID/Investigator# 34864

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Fuerth : Site Reference ID/Investigator# 34869

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Garbsen : Site Reference ID/Investigator# 34874

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Gardelegen : Site Reference ID/Investigator# 34875

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Garmisch-Partenkirchen : Site Reference ID/Investigator# 34876

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Gedern : Site Reference ID/Investigator# 73844

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Germering : Site Reference ID/Investigator# 99801

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Gifhorn : Site Reference ID/Investigator# 58750

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Gilching : Site Reference ID/Investigator# 53202

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Goeda : Site Reference ID/Investigator# 34891

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Goerlitz : Site Reference ID/Investigator# 34892

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Goettingen : Site Reference ID/Investigator# 73845

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Grevenbroich : Site Reference ID/Investigator# 53204

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Gruenstadt : Site Reference ID/Investigator# 34909

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hagen : Site Reference ID/Investigator# 34915

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Halle :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Halle :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Halle : Site Reference ID/Investigator# 34927

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Halle : Site Reference ID/Investigator# 34916

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Halle : Site Reference ID/Investigator# 99807

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Halle : Site Reference ID/Investigator# 58756

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Halle : Site Reference ID/Investigator# 34934

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Halle : Site Reference ID/Investigator# 99798

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Halle : Site Reference ID/Investigator# 34933

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Halle (Saale) : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Hamburg :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Hamburg :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Hamburg : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Hamburg : Site Reference ID/Investigator# 35108

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 34987

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 34948

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 34976

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 58767

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 58742

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 58772

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 35439

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 34990

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 34978

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 34979

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 35002

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 105655

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 99802

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 34975

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 58763

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : Site Reference ID/Investigator# 73837

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamburg : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hamburg : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Hameln : Site Reference ID/Investigator# 35013

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamm : Site Reference ID/Investigator# 99806

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hamm : Site Reference ID/Investigator# 35016

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hannover :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Hannover :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Hannover : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Hannover : Site Reference ID/Investigator# 33787

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hannover : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hannover : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Hanover : Site Reference ID/Investigator# 53145

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hanover : Site Reference ID/Investigator# 35031

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Haßloch :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Haßloch :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Hausham : Site Reference ID/Investigator# 67703

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hechingen : Site Reference ID/Investigator# 67705

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Heidelberg :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Heidelberg :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Heidelberg : Site Reference ID/Investigator# 48885

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Heidelberg : Site Reference ID/Investigator# 33814

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Heidenau : Site Reference ID/Investigator# 81618

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Herne : Site Reference ID/Investigator# 33822

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Herne : Site Reference ID/Investigator# 33821

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hildesheim : Site Reference ID/Investigator# 35473

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Hoyerswerda : Site Reference ID/Investigator# 64002

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Illingen : Site Reference ID/Investigator# 81616

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Iserlohn : Site Reference ID/Investigator# 81615

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Jena :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Jena Lebeda Ost : Site Reference ID/Investigator# 33939

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Karlsruhe : Site Reference ID/Investigator# 53162

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Kassel : Site Reference ID/Investigator# 35485

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Kassel : Site Reference ID/Investigator# 35486

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Kiel : Universitaetsklinikum Schleswig-Holstein Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Kiel : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Kiel :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Kiel :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Kiel : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Kiel : Site Reference ID/Investigator# 33976

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Kiel : Site Reference ID/Investigator# 48901

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Kiel : Site Reference ID/Investigator# 33973

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Kiel : Site Reference ID/Investigator# 38170

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Kiel : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Kiel : Universitaetsklinikum Schleswig-Holstein Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Kirchheim : Site Reference ID/Investigator# 58773

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Kitzingen : Site Reference ID/Investigator# 53149

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Koblenz : Site Reference ID/Investigator# 48903

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Koblenz : Site Reference ID/Investigator# 48897

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Koblenz : Site Reference ID/Investigator# 73836

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Krefeld : Site Reference ID/Investigator# 53275

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Landshut : Site Reference ID/Investigator# 91103

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Lehrte : Site Reference ID/Investigator# 34094

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Leipzig : Site Reference ID/Investigator# 35127

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Leipzig : Site Reference ID/Investigator# 58752

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Leipzig : Site Reference ID/Investigator# 34101

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Leverkusen : Site Reference ID/Investigator# 73833

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Leverkusen : Site Reference ID/Investigator# 58747

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Luebeck : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Luebeck : Site Reference ID/Investigator# 34134

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Luebeck : Site Reference ID/Investigator# 73840

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Luebeck : Site Reference ID/Investigator# 33409

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Luebeck : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Lueneburg : Site Reference ID/Investigator# 34140

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Lÿneburg :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Lÿneburg :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Magdeburg : Site Reference ID/Investigator# 34151

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Magdeburg : Site Reference ID/Investigator# 38168

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Mainz : Site Reference ID/Investigator# 34153

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Mainz : Site Reference ID/Investigator# 34177

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Malente : Site Reference ID/Investigator# 64004

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Mannheim :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Mannheim :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Mannheim : Site Reference ID/Investigator# 64005

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Mannheim : Site Reference ID/Investigator# 35128

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Mannheim : Site Reference ID/Investigator# 34181

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Marburg : Site Reference ID/Investigator# 48887

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Markkleeberg : Site Reference ID/Investigator# 35130

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Markkleeberg : Site Reference ID/Investigator# 35129

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Meitingen : Site Reference ID/Investigator# 105640

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Meuselwitz : Site Reference ID/Investigator# 48904

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Minden : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Minden :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Minden : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Minden : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Minden : Site Reference ID/Investigator# 34204

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Minden : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Minden : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Moenchengladbach : Site Reference ID/Investigator# 53163

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Moenchengladbach : Site Reference ID/Investigator# 53148

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Moers : Site Reference ID/Investigator# 53283

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Moessingen : Site Reference ID/Investigator# 53154

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Muenster : Site Reference ID/Investigator# 48890

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Muenster : Site Reference ID/Investigator# 34045

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Muenster : Site Reference ID/Investigator# 35133

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Muenster : Site Reference ID/Investigator# 99804

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Muenster : Site Reference ID/Investigator# 35301

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Munchen : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Munchen : Research Site

Safety Study of Entocort for Children With Crohn's Disease

München :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

München :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Munich : Site Reference ID/Investigator# 99799

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Munich : Site Reference ID/Investigator# 73839

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Munich : Site Reference ID/Investigator# 81617

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Munich : Site Reference ID/Investigator# 99803

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Munich : Site Reference ID/Investigator# 34033

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Munich : Site Reference ID/Investigator# 58744

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Munich : Site Reference ID/Investigator# 53169

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Munich : Site Reference ID/Investigator# 58754

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Munich : Site Reference ID/Investigator# 34038

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Munich : Site Reference ID/Investigator# 91098

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Munich : Site Reference ID/Investigator# 105637

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Münster :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Münster :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Neubrandenburg : Site Reference ID/Investigator# 35307

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Neubrandenburg : Site Reference ID/Investigator# 35308

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Neumuenster : Site Reference ID/Investigator# 34069

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Neuruppin : Site Reference ID/Investigator# 53172

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Neustadt : Site Reference ID/Investigator# 34073

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Neuwied : Site Reference ID/Investigator# 58769

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Neuwied : Site Reference ID/Investigator# 53159

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Nienburg : Site Reference ID/Investigator# 58759

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Nienburg : Site Reference ID/Investigator# 34156

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Nordhausen : Site Reference ID/Investigator# 34162

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Nuremberg : Site Reference ID/Investigator# 53166

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Nurnberg : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Nurnberg : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Offenburg : Site Reference ID/Investigator# 51866

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Oldenburg : Site Reference ID/Investigator# 33493

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Oldenburg : Site Reference ID/Investigator# 48891

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Oldenburg : Site Reference ID/Investigator# 33494

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Osnabrueck : Site Reference ID/Investigator# 33498

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Osnabrueck : Site Reference ID/Investigator# 35331

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Osnabrueck : Site Reference ID/Investigator# 33500

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Paderborn : Site Reference ID/Investigator# 33501

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Paderborn : Site Reference ID/Investigator# 33502

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Papenburg : Site Reference ID/Investigator# 35337

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Plauen : Site Reference ID/Investigator# 33525

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Potsdam : Site Reference ID/Investigator# 33460

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Potsdam : Site Reference ID/Investigator# 33463

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Radevormwald : Site Reference ID/Investigator# 105639

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Recklinghausen : Site Reference ID/Investigator# 33489

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Regensburg : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Regensburg :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Regensburg :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Regensburg : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Regensburg : Site Reference ID/Investigator# 53344

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Regensburg : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Remscheid : Site Reference ID/Investigator# 58761

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Rinteln : Site Reference ID/Investigator# 53142

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Rostock : Site Reference ID/Investigator# 33924

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Rostock : Site Reference ID/Investigator# 48886

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Rottenburg : Site Reference ID/Investigator# 33932

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Ruedersdorf : Site Reference ID/Investigator# 34012

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Saarbruecken : Site Reference ID/Investigator# 91113

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Sauerlach : Site Reference ID/Investigator# 91115

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Schleswig : Site Reference ID/Investigator# 73838

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Schmalkalden : Site Reference ID/Investigator# 34029

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Schwalmstadt : Site Reference ID/Investigator# 48892

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Schwarz : Site Reference ID/Investigator# 35137

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Schweinfurt : Site Reference ID/Investigator# 33545

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Schwerin : Site Reference ID/Investigator# 33551

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Solingen : Site Reference ID/Investigator# 58760

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Stade :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Stade :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Stade : Site Reference ID/Investigator# 33581

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Stade : Site Reference ID/Investigator# 53286

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Stade : Site Reference ID/Investigator# 33582

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Stralsund : Site Reference ID/Investigator# 33593

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Strausberg : Site Reference ID/Investigator# 48896

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Stuhr : Site Reference ID/Investigator# 48894

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Stuttgart : Site Reference ID/Investigator# 53263

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Stuttgart : Site Reference ID/Investigator# 35385

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Stuttgart : Site Reference ID/Investigator# 33612

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Stuttgart : Site Reference ID/Investigator# 33599

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Teuchern : Site Reference ID/Investigator# 91114

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Traunstein : Site Reference ID/Investigator# 58753

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Tuebingen : Site Reference ID/Investigator# 33630

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Tutzing : Site Reference ID/Investigator# 73848

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Uelzen : Site Reference ID/Investigator# 48893

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Ulm :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Ulm :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Ulm : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Ulm : Site Reference ID/Investigator# 33726

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Ulm : Site Reference ID/Investigator# 58771

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Ulm : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Ulm : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Ulm : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Urbach : Site Reference ID/Investigator# 53164

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Vechta : Site Reference ID/Investigator# 33731

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Vilshofen : Site Reference ID/Investigator# 53251

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Waren : Site Reference ID/Investigator# 33744

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Weilheim : Site Reference ID/Investigator# 53287

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Wiesbaden : Site Reference ID/Investigator# 35409

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Wiesbaden : Site Reference ID/Investigator# 33763

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Wilhelmshaven : Site Reference ID/Investigator# 33769

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Witten : Site Reference ID/Investigator# 67704

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Wittenberge : Site Reference ID/Investigator# 53146

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Wriezen : Site Reference ID/Investigator# 35083

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Wuerselen : Site Reference ID/Investigator# 73849

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Wuerselen : Site Reference ID/Investigator# 81619

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Wuerzburg : Site Reference ID/Investigator# 99805

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Zittau : Site Reference ID/Investigator# 33868

Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine

Athens : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Heraklion : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Kolonaki Athens : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Hong Kong : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Hong Kong : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hong Kong : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Shatin, New Territories : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Bekescsaba : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Bekescsaba : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Békéscsaba :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Békéscsaba :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Budapest : Fovarosi Onkormanyzat Szent Janos Korhaz es Rendelointezet, I. Belgyogyaszat es Gastroenterologia Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Budapest : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Budapest :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Budapest :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Budapest : Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak/I. Belgyogyaszat es Gastroenterologia Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Budapest : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Budapest : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Budapest : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Budapest : Site Reference ID/Investigator# 61053

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Budapest : Site Reference ID/Investigator# 64362

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Budapest : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Budapest : Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak/I. Belgyogyaszat es Gastroenterologia Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Budapest N/A :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Budapest N/A :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Debrecen : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Debrecen : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Debrecen : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Gyongyos : Bugat Pal Korh. Eu-i Szolg. Kozhasznu Nonprofit Kft./Medical Investment Noninvaziv Matrix Belgy. O. Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Gyula :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Hungary : Hungary

A Study of TRK-170 for the Treatment of Crohn's Disease

Mosonmagyarovar :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Mosonmagyaróvár :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Pecs :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Pecs : Site Reference ID/Investigator# 65276

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Szeged : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Szekesfehervar :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Szekesfehervar :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Szeksz Rd N/A :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Szekszard : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Szekszard :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Szekszard : Clinfan Kft. Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Szekszard : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Szekszard : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Szekszard : Clinfan Kft. Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Szekszárd : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Szekszárd : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Szekszárd : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Reykjavik :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Reykjavik :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Dublin : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Dublin : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Dublin 9 : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Dublin 9 :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Galway : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Galway : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Afula : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Haifa :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Haifa : Site Reference ID/Investigator# 38174

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Holon : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Israel : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Israel : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Jerusalem : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Jerusalem :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Jerusalem :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Jerusalem : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Jerusalem : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Jerusalem : Site Reference ID/Investigator# 61275

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Jerusalem : Site Reference ID/Investigator# 61276

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Jerusalem : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Jerusalem : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Kfar Saba : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Kfar Saba :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Kfar Saba : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Kfar Saba : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Petach Tikva : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Petach Tikva : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Petach Tikva : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Petah Tikva :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Ramat Gan : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Ramat-Gan :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Ramat-Gan : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Rehovot :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Rehovot :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Tel Aviv : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Tel Aviv :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Tel Aviv : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Tel Aviv : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Tel Aviv : Site Reference ID/Investigator# 61277

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Tel Aviv : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Tel Aviv : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Zerifin : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Firenze : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Firenze : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Florence : Site Reference ID/Investigator# 46962

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Messina : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Messina : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Milano : Instituto Clinico Humanitas IRCCS

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Napoli : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Padova : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Roma : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Roma : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Roma : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Roma : Research Site

Safety and Maintenance Study of Entocort for Children With Crohn's Disease

Roma : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Rome : Site Reference ID/Investigator# 38178

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Rome : Site Reference ID/Investigator# 38176

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Rozzano : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Rozzano : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Rozzano : Site Reference ID/Investigator# 38177

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Aichi : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Aichi : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Akita : Site Reference ID/Investigator# 81105

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Bunkyo-ku : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Bunkyo-ku : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Chiba : Toho University Sakura Medical Center Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Chiba : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Chiba : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Chiba : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Chikushino :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Chikushino :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Chikushino : Fukuoka University Chikushi Hospital Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Chikushino : Site Reference ID/Investigator# 79700

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Fukuoka :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Fukuoka : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Fukuoka : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Fukuoka : Site Reference ID/Investigator# 79643

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Fukuoka : Site Reference ID/Investigator# 79644

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Gifu : Site Reference ID/Investigator# 79694

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Hamamatsu :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Hamamatsu :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Hamamatsu : Site Reference ID/Investigator# 79645

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Hamamatsu : Site Reference ID/Investigator# 79466

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Hirosaki : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Hirosaki : Site Reference ID/Investigator# 79642

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Hirosaki : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Hiroshima : Site Reference ID/Investigator# 79477

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Hokkaido : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Hyogo : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hyogo : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Iwafune : Site Reference ID/Investigator# 79681

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Kagoshima :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Kagoshima :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Kagoshima : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Kagoshima : Site Reference ID/Investigator# 79450

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Kanagawa : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Kanagawa : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Kashiwa : Site Reference ID/Investigator# 79478

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Kashiwa : Site Reference ID/Investigator# 79675

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Kawagoe : Site Reference ID/Investigator# 79693

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Koriyama : Site Reference ID/Investigator# 79454

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Kumamoto : Site Reference ID/Investigator# 79445

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Kurashiki : Site Reference ID/Investigator# 79636

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Kurume : Research Site

Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan

Kyoto : Site Reference ID/Investigator# 79475

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Minato : Site Reference ID/Investigator# 79456

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Minato-ku : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Minato-ku : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Miyagi : Site Reference ID/Investigator# 68736

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Morioka : Site Reference ID/Investigator# 79446

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Nagakute : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Nagakute : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Nagasaki : Site Reference ID/Investigator# 79656

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Nagoya : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Nagoya : Site Reference ID/Investigator# 79654

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Nagoya : Site Reference ID/Investigator# 79653

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Nagoya : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Neyagawa : Site Reference ID/Investigator# 79459

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Nishinomiya :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Nishinomiya :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Nishinomiya : The Hospital of Hyogo College of Medicine Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Nishinomiya : Site Reference ID/Investigator# 79465

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Ohtsu :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Ohtsu :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Oita :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Oita :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Oita : Site Reference ID/Investigator# 79677

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Oita : Site Reference ID/Investigator# 79695

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Okayama : Site Reference ID/Investigator# 79479

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Osaka : Osaka City University Hospital Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Osaka :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Osaka :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Osaka : Osaka City University Hospital Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Osaka : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Osaka : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Osaka : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Osaka : Site Reference ID/Investigator# 79448

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Osaka : Site Reference ID/Investigator# 79464

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Osaka : Site Reference ID/Investigator# 79449

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Osaka : Osaka City University Hospital Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Osaka-City :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Osaka-City :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Osakasayama : Site Reference ID/Investigator# 79657

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Otsu : Shiga University of Medical Science Hospital Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Otsu : Site Reference ID/Investigator# 79673

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Saga : Site Reference ID/Investigator# 79674

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Saitama : Site Reference ID/Investigator# 79455

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Sakura :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Sakura :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Sakura : Site Reference ID/Investigator# 79476

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Sapporo :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Sapporo :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Sendai : National Hospital Organization Sendai Medical Center Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Sendai : National Hospital Organization Sendai Medlical Center Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Shinjuku :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Shinjuku-ku : Keio University Hospital Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Shinjuku-ku : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Shinjuku-ku : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Shinjyuku-ku : Social Insurance Chuo General Hospital Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Shinjyuku-ku : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Shunan : Site Reference ID/Investigator# 79453

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Suita : Site Reference ID/Investigator# 79634

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Takamatsu : Site Reference ID/Investigator# 79451

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Tokyo :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Tokyo :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Tokyo : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Tokyo : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Tokyo : Site Reference ID/Investigator# 79699

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Tokyo : Site Reference ID/Investigator# 79641

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Toyohashi : Site Reference ID/Investigator# 81102

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Toyota : Site Reference ID/Investigator# 81100

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Yokkaichi :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Yokkaichi :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Yokkaichi : Site Reference ID/Investigator# 79458

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Yokohama : Site Reference ID/Investigator# 79473

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

Busan : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Daegu :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Daegu :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Daegu : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Daegu : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Daegu : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Gyeonggi-Do :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Gyeonggi-Do :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Gyeonggi-do : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Pusan : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Pusan : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Seoul : Samsung Medical Center, Division of Gastroenterology, Department of Internal Medicine Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Seoul :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Seoul :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Seoul : Severance Hospital, Yonsei University Health System Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Seoul : Seoul National University Hospital,Division of Gastroenterology,Department of Internal Medicine Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Seoul : Samsung Medical Center, Division of Gastroenterology, Department of Internal Medicine Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Seoul : ASAN Medical Center,Division of Gastroenterology,Department of Internal Medicine Updated

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Seoul : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Seoul : Samsung seoul Hospital

Clinical Trials of Autologous Cultured Adipose-derived Stem Cells (ANTG-ASC) on Complex Fistula

Seoul : Seoul National University Hospital

Clinical Trials of Autologous Cultured Adipose-derived Stem Cells (ANTG-ASC) on Complex Fistula

Seoul : Seoul Asan Hospital

Clinical Trials of Autologous Cultured Adipose-derived Stem Cells (ANTG-ASC) on Complex Fistula

Seoul : Seoul Saint Mary's Hospital

Clinical Trials of Autologous Cultured Adipose-derived Stem Cells (ANTG-ASC) on Complex Fistula

Seoul : DaeHang Hospital

Clinical Trials of Autologous Cultured Adipose-derived Stem Cells (ANTG-ASC) on Complex Fistula

Seoul : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Seoul : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Seoul : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Seoul : Severance Hospital, Yonsei University Health System Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Seoul : ASAN Medical Center,Division of Gastroenterology,Department of Internal Medicine Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Seoul : Samsung Medical Center, Division of Gastroenterology, Department of Internal Medicine Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Wonju : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Wonju : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Latvia : Latvia

A Study of TRK-170 for the Treatment of Crohn's Disease

Alkmaar : Site Reference ID/Investigator# 38181

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Amersfoort : Site Reference ID/Investigator# 38179

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Amsterdam :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Amsterdam :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Amsterdam : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Amsterdam : VUMC

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Amsterdam : AMC

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Amsterdam : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Amsterdam : Site Reference ID/Investigator# 43042

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Amsterdam : Pfizer Investigational Site Updated

Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs

Amsterdam : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Amsterdam : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Amsterdam Zuidoost :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Groningen : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Groningen : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Leiden : Site Reference ID/Investigator# 38180

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Maastricht :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Maastricht :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Maastricht : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Maastricht : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Rotterdam :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Rotterdam :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Sittard-Geleen : Site Reference ID/Investigator# 93353

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

The Netherlands : The Netherlands

A Study of TRK-170 for the Treatment of Crohn's Disease

Utrecht : UMCU

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Auckland :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Auckland :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Christchurch : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Christchurch :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Christchurch :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Christchurch : University of Otago

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Christchurch : University of Otago

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Dunedin :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Dunedin :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Dunedin : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Grafton :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Grafton :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Hamilton : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Hamilton :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Hamilton : Waikato Hospital

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Hamilton : Waikato Hospital

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Hastings :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Hastings :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Lower Hutt : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Lower Hutt : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Lower Hutt : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Milford : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Otahuhu, Auckland : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Otahuhu, Auckland : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Plenty :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Plenty :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Tauranga. : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Tauranga. : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Wellington : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Wellington :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Bergen : Department of Medicine, Haukeland University Hospital

Contrast Enhanced Ultrasonography (CEUS) of Patients With Crohn's Disease

Gjettum : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Gjettum : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Norway : Norway

A Study of TRK-170 for the Treatment of Crohn's Disease

Oslo : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Rud : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Bydgoszcz :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Bydgoszcz : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Bydgoszcz : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Bydgoszczy : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Bydgoszczy : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Czestochowa :

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Elblag :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Elblag :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Krakow :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Krakow :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Krakow : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Krakow : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Lodz :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Lodz :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Lodz : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Lublin : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Poland : Poland

A Study of TRK-170 for the Treatment of Crohn's Disease

Rzeszow : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Rzeszow : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Sopot : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Torun : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Warsaw : Site Reference ID/Investigator# 63364

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Warsaw : Site Reference ID/Investigator# 60903

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Warszawa :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Warszawa :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Warszawa : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Warszawa : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Warszawa : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Warszawa : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Wroclaw : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Wroclaw : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Wroclaw : Research Site

Safety Study of Entocort for Children With Crohn's Disease

Wroclaw : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Lisboa : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Porto : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

San Juan : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Bucharest : Site Reference ID/Investigator# 69643

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Bucharest : Site Reference ID/Investigator# 69642

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Romania : Romania

A Study of TRK-170 for the Treatment of Crohn's Disease

Timisoara : Site Reference ID/Investigator# 69644

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Ekaterinburg : 28

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Ekaterinburg : 13

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Kazan : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Kazan : 12

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Kazan : 16

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Moscow :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Moscow :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Moscow : 11

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Moscow : 5

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Moscow : 25

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Moscow : 8

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Moscow : 24

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Moscow : 14

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Moscow : 9

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Moscow : 7

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Moscow : 31

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Nizhniy Novgorod :

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Nizhniy Novgorod : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Nizhniy Novgorod : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Novgorod : 23

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Novosibirsk :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Novosibirsk :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Orenburg : 20

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Orenburg : 21

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Orenburg : 29

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Rostov-on-Don : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Saint Petersburg : 6

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Saint Petersburg : 1

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Saint Petersburg : 3

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Saint Petersburg : 4

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Saint-Petersburg :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Samara : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Samara : 18

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Samara : 15

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Shakhty : 17

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

St. Petersburg : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

St. Petersburg : 19

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

St. Petersburg : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

St.Petersburg : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Taganrog : 10

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Tolyatti : 26

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Ufa : 32

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Ufa : 22

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Ufa : 27

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Ulyanovsk : 30

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Yaroslavl : 2

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD)

Belgrade :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Belgrade :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Belgrade : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Belgrade : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Beograd :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Serbica : Serbia

A Study of TRK-170 for the Treatment of Crohn's Disease

Bratislava : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Bratislava : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Bratislava : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Nitra : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Nitra : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Nitra : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Nitra : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Nitra : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Nove Mesto nad Vahom : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Nove Mesto nad Vahom : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Nove Mesto nad Vahom : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Nove Mesto nad Vahom : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Presov : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Presov : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Ruzomberok :

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Trnava : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Bellville : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Cape Town :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Cape Town :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Cape Town Western Cape :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Claremont : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Claremont : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Claremont : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Claremont : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Durban :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Durban :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Durban : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Durban : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Durban : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Durban : Parklands Medical Centre Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Observatory : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Panorama : Local Institution

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Pretoria :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Pretoria :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Somerset West Western Cape :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Barcelona : Hospital Clinic de Barcelona Updated

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Barcelona :

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Barcelona : Hospital Clinic de Barcelona

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Barcelona : Site Reference ID/Investigator# 62624

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Barcelona : Hospital Clinic de Barcelona Updated

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Cordoba : Hospital Universitario Reina Sofia

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Elche : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Elche : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Fuenlabrada (Madrid) : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Fuenlabrada (Madrid) : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Huelva : Hospital Juan Ramon Jimenez

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Madrid :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Madrid :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Madrid : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Madrid : Hospital Clinico San Carlos

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Madrid : Hospital 12 de Octubre

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Madrid : Hospital Universitario La Paz

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Madrid : Hospital La Princesa

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Madrid : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Madrid : Site Reference ID/Investigator# 38185

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Madrid : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Madrid : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Majadahonda : Pfizer Investigational Site Updated

A Study To Monitor Long-Term Treatment With PF-00547659

Majadahonda : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Pontevedra : Hospital de Montecelo

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Sabadell :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Sabadell : Pfizer Investigational Site Updated

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease

Sabadell (Barcelona) : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Santiago De Compostela :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Seville : Hospital Virgen del Rocio

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Valencia : Hospital Universitario La Fe

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Valencia : Hospital de Sagunto

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease

Zaragoza : Site Reference ID/Investigator# 38186

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Gothenburg : Site Reference ID/Investigator# 39065

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Lund : Site Reference ID/Investigator# 39064

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Lund : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Lund : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Orebro : Site Reference ID/Investigator# 39066

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Stockholm : Site Reference ID/Investigator# 39062

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Stockholm : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Stockholm : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Sweden : Sweden

A Study of TRK-170 for the Treatment of Crohn's Disease

Uppsala : Site Reference ID/Investigator# 39082

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Bern : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Bern : Site Reference ID/Investigator# 38192

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Zuerich : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Zuerich : Pfizer Investigational Site Updated

B0151003 Open-Label Extension Study

Zurich :

A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's Disease

Zurich : Site Reference ID/Investigator# 38191

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Zürich : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Zürich : University Hospital

Randomized, Double-blind, Placebo-controlled Study in Patients With Fistulizing Crohn's Disease

Taipei : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Istanbul : Site Reference ID/Investigator# 93553

Improvement of Work Productivity and Quality of Life With Anti-Tumor Necrosis Factor (TNF) Therapies Used in Crohn's Disease in Routine Clinical Practice in Turkey.

Chernivtsi : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Dnipropetrovsk : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Dnipropetrovsk : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Donetsk : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Donetsk : Site Reference ID/Investigator# 68925

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Donetsk : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Kharkiv : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Kharkiv : Site Reference ID/Investigator# 69266

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Kharkiv : Site Reference ID/Investigator# 70033

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Kharkiv : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Kyiv : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Lviv : Site Reference ID/Investigator# 68926

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Odesa : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Odesa : Site Reference ID/Investigator# 70034

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Poltava : Site Reference ID/Investigator# 68922

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Simferopol : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Simferopol : Site Reference ID/Investigator# 69265

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Ukraine : Ukraine

A Study of TRK-170 for the Treatment of Crohn's Disease

Vinnytsya : GSK Investigational Site Updated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Vinnytsya : Site Reference ID/Investigator# 68924

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Vinnytsya : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Birmingham :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Birmingham :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Brighton :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Brighton :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Bristol :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Bristol :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Bristol : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Bristol : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Cambridge : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Cambridge :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Cambridge :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Cardiff :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Coventry : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Edinburgh : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Edinburgh : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Exeter :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Glasgow : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Gloucester :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Gloucester :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Harrow :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Harrow : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Liverpool :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Liverpool :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Liverpool : Site Reference ID/Investigator# 43987

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

London : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

London :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

London :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

London : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Manchester : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Manchester :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Manchester :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Manchester : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Manchester : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Newcastle upon Tyne : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Newcastle-upon-Tyne : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Newcastle-upon-Tyne : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Norwich :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Norwich :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Norwich : Research Site

AMG 181 in Subjects With Moderate to Severe Crohn's Disease

Nottingham : Research Site

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MT-1303 in Subjects With Inflammatory Bowel Disease

Nottinghamshirecc :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Nottinghamshirecc :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Oxford :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Oxford :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Oxford : Site Reference ID/Investigator# 38196

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Oxford : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Oxford : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Salford : GSK Investigational Site

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Salford : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Shrewsbury :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Shropshire :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Southampton : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Southampton :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Southampton :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Wolverhampton : Pfizer Investigational Site Updated

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Worthing : Worthing Hospital

Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)

Crohn's Disease Clinical Trials

Alabama

Arizona

Arkansas

California

Colorado

Connecticut

District of Columbia

Florida

Georgia

Idaho

Illinois

Indiana

Iowa

Kansas

Kentucky

Louisiana

Maine

Maryland

Massachusetts

Michigan

Minnesota

Mississippi

Missouri

Nebraska

Nevada

New Hampshire

New Jersey

New York

North Carolina

Ohio

Oklahoma

Oregon

Pennsylvania

South Carolina

Tennessee

Texas

Utah

Vermont

Virginia

Washington

West Virginia

Wisconsin

Australia

Austria

Belgium

Brazil

Bulgaria

Canada

Croatia

Czech Republic

Denmark

Estonia

France

Germany

Greece

Hong Kong

Hungary

Iceland

Ireland

Israel

Italy

Japan

Korea, Republic of

Latvia

Netherlands

New Zealand

Norway

Poland

Portugal

Puerto Rico

Romania

Russian Federation

Serbia

Slovakia

South Africa

Spain

Sweden

Switzerland

Taiwan